Stay updated on Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial

Sign up to get notified when there's something new on the Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The clinical trial page now displays the completed study record for nivolumab, cabiralizumab, and gemcitabine in Stage IV pancreatic cancer, including study design, participant criteria, outcome measures, and a protocol document.
    Difference
    51%
    Check dated 2026-11-07T12:30:57.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The footer revision changed from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T13:09:41.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    A sitewide NIH notice was added announcing a terminology transition from “Artificial Intelligence (AI)” to “Super Intelligence (SI)” and linking to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T12:53:25.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The footer’s site revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T13:55:04.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The footer revision indicator updates from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T13:52:37.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Access to the study page now shows a 403 Forbidden error, replacing the study content with an access-denied screen. The page content includes explicit 403 messaging and related HTML structure indicating forbidden access.
    Difference
    18%
    Check dated 2026-09-19T22:16:06.000Z thumbnail image

Stay in the know with updates to Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab + Cabiralizumab in Pancreatic Cancer Clinical Trial page.